脑机接口市场发展情况如何？未来的产业发展方向是什么？翔宇医疗如何紧抓市场机遇？带着这些问 题，《证券日报》记者走进翔宇医疗，与公司董事长何永正展开探讨与交流。 脑机接口赋能主动康复 脑机接口作为康复领域的创新技术，正引领着康复行业从"被动康复"转向"主动康复"。该技术通过实时 捕捉脑电信号并解码，驱动外部设备对大脑进行针对性刺激，形成"感知－响应－强化"的神经发育闭 环，让康复训练更高效、更精准。 本报记者 肖艳青 作为连接大脑与外部设备的颠覆性技术，脑机接口正被全球科技界视为重构人机交互范式的核心方向。 在政策支持、技术突破与资本涌入等多重因素驱动下，脑机接口产业发展提速，应用前景已从医疗康复 延伸至消费电子等多元场景，展现出巨大的市场潜力。 河南翔宇医疗设备股份有限公司（以下简称"翔宇医疗"）凭借在康复医疗领域的技术积淀，自2015年起 便开始布局脑机接口及类脑研究。目前该公司率先实现脑机接口技术的临床转化，相关产品已进入国内 超600家三级甲等医院，覆盖神经康复、运动功能重建等核心领域，成为国内脑机接口医疗应用的领军 企业。 "主动康复效果强于被动康复。"何永正表示，"脑机接口技术是一种让大脑持续深度参 ...

Core Viewpoint - The medical device sector experienced a rise of 0.54% on January 21, with N Aisheren leading the gains, while the Shanghai Composite Index increased by 0.08% and the Shenzhen Component Index rose by 0.7% [1] Group 1: Stock Performance - N Aisheren (code: 920050) closed at 44.04, with a remarkable increase of 175.59% and a trading volume of 141,600 shares [1] - Tianzhihang (code: 688277) saw a rise of 12.38%, closing at 23.88 with a trading volume of 376,500 shares [1] - Xishan Technology (code: 688576) increased by 11.18%, closing at 76.80 with a trading volume of 34,000 shares [1] - Kangzhong Medical (code: 688607) rose by 10.91%, closing at 59.67 with a trading volume of 76,200 shares [1] - Shuoshi Biological (code: 6658889) increased by 9.74%, closing at 84.84 with a trading volume of 70,300 shares [1] Group 2: Capital Flow - The medical device sector saw a net inflow of 300 million yuan from institutional investors, while retail investors experienced a net outflow of 430 million yuan [2] - Major stocks like Sainuo Medical (code: 688108) had a net inflow of 69.18 million yuan from institutional investors, but a net outflow of 44.76 million yuan from retail investors [3] - LePu Medical (code: 300003) had a net inflow of 48.54 million yuan from institutional investors, with a slight net inflow of 0.52 million yuan from retail investors [3]

Market Performance - On January 21, the three major A-share indices collectively rose, with the Shanghai Composite Index increasing by 0.08% to 4116.94 points, the Shenzhen Component Index rising by 0.7% to 14255.13 points, and the ChiNext Index up by 0.54% to 3295.52 points [1] Fund Manager Changes - On January 21, there were 25 fund manager changes, with 23 fund products announcing departures of fund managers, involving 11 managers. In the past 30 days (December 22 to January 21), 587 fund products experienced manager changes [3] - The reasons for the changes included 9 managers leaving due to job changes and 2 due to product expiration [3] New Fund Managers - On January 21, 32 fund products announced new fund manager appointments, involving 14 managers. Notably, Xu Chengcheng from Industrial Bank has managed funds totaling 2.169 billion yuan, with the highest return of 758.05% from the Guotai Guozheng Food and Beverage Industry Fund [5] Fund Research Activity - In the past month (December 22 to January 21), Huaxia Fund conducted the most company research, engaging with 54 listed companies, followed by Bosera Fund with 45 and Southern Fund with 39 [6][7] - The automotive parts industry was the most researched sector, with 173 instances, followed by the chemical products industry with 149 [6][7] Recent Company Focus - In the last week (January 14 to January 21), the most researched company was Naipu Mining, with 41 fund institutions participating in the research. Other notable companies included Tiancheng Technology and Dike Co., with 36 and 31 fund institutions respectively [8][9]

Core Viewpoint - The rehabilitation industry is viewed as a "golden track" with significant growth potential, driven by brain-computer interface (BCI) technology, which is expected to reshape the industry landscape [1] Group 1: Technological Innovation - The company focuses on three cutting-edge areas: brain-computer interfaces, rehabilitation robots, and AI medical technology, with BCI technology accelerating commercialization [2] - A comprehensive product matrix for rehabilitation robots has been established, with plans to launch 5-6 new products by 2026, including various specialized robots [2][4] - The company has initiated a brain science laboratory and developed five technical platforms to enhance its BCI technology, achieving compatibility between EEG devices and rehabilitation equipment [4] Group 2: Research and Development Investment - The company plans to maintain R&D investment at over 20% of revenue for the next 3-5 years, with more than 30% allocated to frontier technology research [5] - In the first three quarters of 2025, R&D investment reached approximately 49.09 million yuan, a year-on-year increase of 27.67%, accounting for 27.58% of quarterly revenue [5] Group 3: Market Transformation - The company has partnered with over 600 leading hospitals to establish BCI rehabilitation treatment and clinical research centers, enhancing treatment precision and effectiveness [6] - The company is transitioning from passive to active rehabilitation models, leveraging BCI technology to empower various rehabilitation products [6] Group 4: International Expansion - The company is accelerating its international market strategy, with overseas sales expected to double in 2024 compared to 2023, aiming for international revenue to account for over 30% by 2030 [7] - The company is pursuing compliance certifications such as EU CE and US FDA to facilitate international market entry and is exploring partnerships and acquisitions to enhance its global presence [7] Group 5: Ecosystem Development - The company is focused on building a comprehensive rehabilitation ecosystem, emphasizing the integration of BCI technology into rehabilitation devices, which is seen as essential for future products [8] - The trend towards lightweight, portable, and home-based rehabilitation devices is expected to drive significant growth in the home rehabilitation market [8] Group 6: Industry Integration - The company plans to strengthen its supply chain for core components and aims to execute 3-5 mergers and acquisitions between 2026 and 2030 to integrate high-growth startups [9] - The company targets to establish chain rehabilitation hospitals featuring BCI and rehabilitation robots, with a goal of achieving over 20% of service revenue by 2030 [9]

Core Viewpoint - The rehabilitation industry is viewed as a "golden track" with significant growth potential, driven by brain-computer interface (BCI) technology, which is expected to reshape the industry landscape [1] Group 1: Technological Innovation - The company focuses on three cutting-edge areas: brain-computer interfaces, rehabilitation robots, and AI medical technology, with BCI technology accelerating commercialization [2] - A comprehensive product matrix in rehabilitation robotics has been established, with plans to launch 5-6 medical device registrations by 2026 [2] - The company has initiated a brain science laboratory and developed five technical platforms to enhance BCI technology integration with rehabilitation equipment [3] - Continuous R&D investment is planned to remain above 20% of revenue over the next 3-5 years, with a significant portion allocated to frontier technology research [4] Group 2: Market Transformation - The company has partnered with over 600 leading hospitals to establish BCI rehabilitation treatment and clinical research centers, aiming to create regional treatment benchmarks [5] - The integration of BCI technology into multi-joint exoskeleton robots and various rehabilitation products is expected to enhance treatment precision and effectiveness [6] - A dual strategy of deepening medical institution engagement while expanding into outpatient markets is being implemented, targeting public hospitals, private hospitals, and rehabilitation institutions [6] Group 3: International Expansion - The company is accelerating its international business, with overseas sales expected to double in 2024 compared to 2023, aiming for international revenue to account for over 30% by 2030 [6][7] - Compliance with international certification standards, such as EU CE and US FDA, is being prioritized to facilitate market entry [7] Group 4: Ecosystem Development - The company is focused on building a comprehensive rehabilitation ecosystem, emphasizing the importance of BCI technology in future rehabilitation devices [8] - The trend towards lightweight, portable, and home-based rehabilitation devices is noted, with a vision to integrate rehabilitation equipment into everyday household items [8] Group 5: Industry Integration - Strengthening the supply chain for core components like chips and sensors is a priority, along with plans for mergers and acquisitions to consolidate industry resources [9] - The company aims to establish chain rehabilitation hospitals featuring BCI and rehabilitation robotics, targeting a service revenue contribution of over 20% by 2030 [9]

Group 1 - The article discusses the current state of the market, highlighting significant fluctuations in stock prices and investor sentiment [1] - It mentions a recent surge in technology stocks, which have outperformed other sectors, contributing to overall market gains [1] - The report indicates that economic indicators, such as unemployment rates and consumer spending, are showing signs of recovery, which may bolster investor confidence [1] Group 2 - The article provides data on quarterly earnings reports from major companies, revealing a mixed performance across different industries [1] - It notes that companies in the healthcare sector have reported strong growth, while those in the retail sector are facing challenges due to supply chain disruptions [1] - The analysis includes projections for future earnings, suggesting that technology and healthcare will continue to lead the market, while retail may struggle in the short term [1]

Core Viewpoint - The rehabilitation industry is viewed as a "golden track" with significant growth potential, and brain-computer interface (BCI) technology is emerging as a disruptive force reshaping the industry landscape [1] Group 1: Technological Innovation - The company focuses on three cutting-edge areas: brain-computer interfaces, rehabilitation robots, and AI medical technology, with BCI technology accelerating commercialization [2] - A comprehensive product matrix in rehabilitation robotics has been established, with plans to launch 5-6 medical device registrations by 2026 [2] - The company has initiated a brain science laboratory and developed five technical platforms to enhance BCI technology integration with rehabilitation equipment [3] - Continuous R&D investment is planned to remain above 20% of revenue over the next 3-5 years, with a significant portion allocated to frontier technology research [4] Group 2: Market Transformation - The company has partnered with over 600 leading hospitals to establish BCI rehabilitation treatment and clinical research centers, enhancing treatment precision and effectiveness [5] - A dual strategy of deepening medical institution engagement and expanding outpatient markets is being implemented, targeting various sectors including private hospitals and rehabilitation institutions [5] - International market expansion is accelerating, with a goal to double overseas sales in 2024 and achieve over 30% of revenue from international markets by 2030 [5][6] Group 3: Ecosystem Development - The company is focused on building a comprehensive rehabilitation ecosystem, emphasizing the importance of BCI technology in future rehabilitation devices [7] - There is a shift towards lightweight, portable, and home-based rehabilitation devices, with a vision to integrate rehabilitation equipment into everyday household items [7] - Industry chain integration is a key strategy for enhancing competitiveness, with plans for mergers and acquisitions to consolidate high-growth startups and expand rehabilitation services [8]

Core Insights - The rehabilitation industry is viewed as a "golden track" with significant growth potential, driven by brain-computer interface (BCI) technology, which is expected to reshape the industry landscape [1][4]. Group 1: Technological Innovation - The company focuses on three cutting-edge areas: brain-computer interfaces, rehabilitation robots, and AI medical technology, with BCI technology accelerating commercialization [1][2]. - A comprehensive product matrix for rehabilitation robots has been established, with plans to obtain medical device registration for 5-6 products by 2026, including various types of therapeutic robots [1][2]. - The company has initiated a dedicated research platform to enhance compatibility between rehabilitation equipment and BCI algorithms, emphasizing the importance of technical collaboration [2]. Group 2: Research and Development Investment - The company plans to maintain R&D investment at over 20% of revenue for the next 3-5 years, with more than 30% allocated to frontier technology research [3]. - In the first three quarters of 2025, R&D investment reached approximately 49.09 million yuan, a year-on-year increase of 27.67%, accounting for 27.58% of quarterly revenue [3]. Group 3: Market Expansion and Strategy - The company has established partnerships with over 600 leading hospitals in China to create centers for BCI rehabilitation treatment and clinical research, enhancing its market penetration [3]. - A dual strategy of deepening relationships with medical institutions while expanding into outpatient markets is being employed, targeting private hospitals, elderly care facilities, and specialized sectors [3][4]. Group 4: International Market Development - The international business of rehabilitation equipment is experiencing rapid growth, with plans to double sales in 2024 compared to 2023 and aim for over 30% of revenue from international markets by 2030 [4]. - The company is working on compliance certifications such as EU CE and US FDA to facilitate international market entry and is exploring partnerships for overseas expansion [4]. Group 5: Ecosystem Development - The company is focused on building a comprehensive rehabilitation ecosystem, leveraging BCI technology as a core driver for industry transformation [4][5]. - There is a shift towards lightweight, portable, and home-based rehabilitation devices, with a vision to integrate rehabilitation equipment into everyday household items [5]. - The company plans to enhance its supply chain for core components and aims to execute 3-5 mergers and acquisitions between 2026 and 2030 to consolidate industry resources [5].

Group 1 - The A-share market has seen structural investment opportunities emerge since 2026, particularly in sectors like brain-computer interfaces, commercial aerospace, and embodied intelligence [1][2] - Companies such as Xiangyu Medical and Haitan Ruisheng have become popular among institutional investors, with Xiangyu Medical receiving 208 institutional visits, the highest in its category [1][2] - Haitan Ruisheng is optimistic about the embodied intelligence data sector and has formed a dedicated team to develop related business, collaborating with various robotics manufacturers and tech giants [3] Group 2 - The commercial aerospace sector is also attracting attention, with Chaojie Co. receiving nearly 130 institutional visits in a short period, focusing on its rocket structural components and production capacity [3] - The overall situation shows that 373 listed companies have received institutional research since the beginning of 2026, with electronics and machinery equipment industries being the most popular [4] - Despite recent market adjustments, industry analysts believe that policy support and technological breakthroughs will continue to drive growth in sectors like brain-computer interfaces and commercial aerospace [4][5]

Core Viewpoint - Xiangyu Medical's export business is primarily focused on Southeast Asia, the Middle East, Central Asia, South America, and Africa, with a relatively small share in the European Union [1] Group 1 - The company's overseas business is in its early stages but is maintaining a high growth trend [1] - Xiangyu Medical is expanding its medical market through international exhibitions and overseas distributors [1] - The company is actively promoting CE certification and other product access work [1]